Claims
- 1. A pharmaceutical composition for transdermal or transmucosal administration comprising a nonaqueous mixture of a polymer, a drug and a permeation enhancing amount of a fatty acid ester or fatty alcohol ether of a C.sub.2 to C.sub.4 alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of about 8 to 22 carbon atoms.
- 2. The pharmaceutical composition of claim 1 wherein the composition is in the form of a solid state transdermal drug delivery device.
- 3. The pharmaceutical composition of claim 2 wherein the drug is estradiol or fentanyl.
- 4. The pharmaceutical composition of claim 2 wherein the device is a laminated composite of a reservoir layer and a pressure sensitive adhesive layer.
- 5. The pharmaceutical composition of claim 4 wherein the drug and the fatty acid ester or fatty alcohol ether are both contained primarily in the reservoir layer.
- 6. The pharmaceutical composition of claim 1 wherein the ester is a monoester and the ether is a monoether.
- 7. A pharmaceutical composition for transdermal or transmucosal administration comprising a nonaqueous mixture of a polymer, a drug and a permeation enhancing amount of a fatty acid monoester of propylene glycol.
- 8. The pharmaceutical composition of claim 7 wherein the fatty acid monoester of propylene glycol is propylene glycol monolaurate.
- 9. The pharmaceutical composition of claim 8 wherein the drug is estradiol or fentanyl.
- 10. A method of enhancing the permeation of a body surface to a drug administered to the surface comprising coadministering to the surface a permeation enhancing amount of a fatty acid ester or a fatty alcohol ether of a C.sub.2 to C.sub.4 alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of about 8 to 22 carbon atoms and wherein said ester or ether is administered from a nonaqueous mixture comprising a polymer and said ester or ether.
- 11. The method of claim 10 wherein the drug is estradiol or fentanyl.
- 12. A method of enhancing the permeation of skin to estradiol or fentanyl comprising coadministering to the skin a permeation enhancing amount of propylene glycol monolaurate from a nonaqueous mixture of estradiol or fentanyl, a polymer, and propylene glycol monolaurate.
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of copending U.S. patent application Ser. No. 079,801, filed July 30, 1987 which in turn is a continuation-in-part of U.S. patent application Ser. No. 041,793, filed Apr. 23, 1987 which is a continuation-in-part of U.S. patent application Ser. No. 945,356, filed Dec. 22, 1986, all of which are now abandoned.
This invention is in the field of transdermal drug-delivery. More particularly it relates to a transdermal drug-delivery device in the form of a solid state laminated composite that is adapted to be adhered to the skin and that includes a multiplicity of spaced resilient structural laminas that provide the device with mechanical properties that enable the device to stretch in concert with the area of skin to which it is adhered and which facilitate its handling prior to application. One embodiment of the invention is particularly adapted for administering estradiol transdermally. Another is particularly adapted for administering fentanyl or fentanyl derivatives transdermally.
A variety of devices have been proposed or used for administering drugs transdermally. These devices are generally laminated composites that include a reservoir layer that contains the drug, a pressure-sensitive adhesive layer by which the device is attached to the skin, and a backing layer that forms the outer "skin" of the device. Depending upon the inherent permeability of the skin to a particular drug, the device may also include means for coadministering a percutaneous absorption enhancer or an element, such as a membrane interposed between the reservoir and the skin, that regulates the rate at which the drug and/or the enhancer is administered to the skin.
U.S. Pat. Nos. 4,379,454 and 4,460,372 describe a device for coadministering a drug and a percutaneous absorption enhancer transdermally. The drug is presented to the skin at a rate in excess of that which the skin is inherently capable of absorbing and the enhancer is presented to the skin at a substantially constant rate that is sufficient to permit the skin to pass therapeutic levels of drug to circulation. The device includes a membrane interposed between a drug-and enhancer-containing reservoir layer and a pressure-sensitive adhesive layer that regulates the rate at which the enhancer is presented to the skin. In the commercial estradiol embodiment of this device (marketed under the mark ESTRADERM) the enhancer is ethanol and the estradiol-ethanol mixture is contained in the reservoir in a fluid form. Using such a form complicates the procedures for manufacturing the device and detracts from the ability to optimize certain physical characteristics of the device such as thickness, resiliency, and adhesiveness, that are associated with wearability.
Other patent publications relating to devices for administering estradiol transdermally are German Patent Publication Nos. 3 315 245 and 3 315 272, European Patent Publication Nos. 0013606 and 0040861 and U.S. Pat. No. 4,438,139.
Patent publications relating to transdermal delivery of opioids in general and fentanyl or fentanyl derivatives or analogs (sufentanil, carfentanil, lofentanil, and alfentanil) are EPA No. 0171742 and U.S. Pat. Nos. 4,588,580 and 4,626,539.
U.S. Pat. No. 4,435,180 describes a transdermal drug-delivery device comprising a body of a mixture of elastomer and drug, the body being in a form such as an arm or wrist band which inherently creates a compressive force when worn to keep the body firmly in contact with the skin.
The focus of much of the prior art relating to transdermal drug delivery has been on the release kinetics of the drug or enhancer from the device. Because of this the design of most prior devices has centered about the achievement of desired drug release kinetics, and, for the most part has ignored or given only secondary consideration to mechanical properties that enhance its wearability and cosmetic acceptability. In this regard, the present invention provides a transdermal drug-delivery device that provides acceptable drug release kinetics as well as resiliency, thinness and, when permitted, breathability.
The invention is a transdermal drug-delivery device in the form of a solid state laminated composite adapted to be adhered to a predetermined area of unbroken skin and having mechanical properties that enable it to expand and contract in concert with the normal expansion and contraction of said area of skin comprising:
(a) at least two spaced structural laminas of a resilient polymer, said laminas providing the composite with said mechanical properties;
(b) at least one lamina of a viscoelastic hydrophobic polymer optionally in which (i) a drug and/or (ii) an agent that enhances the solubility of the drug in the viscoelastic hydrophobic polymer and/or is a percutaneous absorption enhancer that increases the permeability of the skin to the drug is dispersed and at least partly dissolved, the viscoelastic hydrophobic polymer lamina being positioned between the structural laminas with the structural lamina(s) underlying the viscoelastic hydrophobic polymer lamina(s) providing no rate-controlling barrier to diffusion of drug and/or agent from the viscoelastic hydrophobic polymer lamina(s) to the skin; and
(c) a lamina of a pharmaceutically acceptable pressure-sensitive adhesive optionally in which (i) said drug and/or (ii) said agent is dispersed and at least partly dissolved, one face of the pressure-sensitive adhesive lamina defining the basal surface of the composite and contacting and adhering to the area of unbroken skin when the device is in use, said pressure-sensitive adhesive lamina providing no rate-controlling barrier to diffusion of the drug and/or agent from the device to the skin, with the proviso that at least one of said viscoelastic hydrophobic polymer lamina(s) and said pressure-sensitive adhesive lamina contains the drug.
Prior to use the device also includes a release liner lamina that covers the basal surface of the pressure-sensitive adhesive lamina and is adapted to be removed from the device to expose the basal surface of the pressure-sensitive adhesive lamina.
In embodiments which involve a steroidal drug, such as estradiol, or certain opioids such as fentanyl and fentanyl analogs, it may be necessary that the device be a sufficient barrier to water vapor transmission to cause the area of skin to become hydrated and thus more permeable to the drug. In other embodiments involving drugs that do not require that the skin be hydrated, the components of the device may be made from water vapor permeable materials so as to make the device breathable.
Another aspect of this invention is a pharmaceutical composition for transdermal or transmucosal administration comprising a drug and a permeation enhancing amount of a fatty acid ester or fatty alcohol of a C.sub.2 to C.sub.4 alkanediol where each fatty acid or fatty alcohol portion of the ester or ether is of about 8 to 22 carbon atoms.
Still another aspect of the invention is a method of enhancing the permeation of a body surface to a drug administered to the surface comprising coadministering to the surface a permeation enhancing amount of a fatty acid ester or a fatty alcohol ether of a C.sub.2 to C.sub.4 alkanediol where each fatty acid or fatty alcohol portion of the ester of ether is of about 8 to 22 carbon atoms.
US Referenced Citations (26)
Foreign Referenced Citations (4)
| Number |
Date |
Country |
| 0171742 |
Feb 1980 |
EPX |
| 0020117 |
Dec 1980 |
EPX |
| 59-84817 |
Nov 1982 |
JPX |
| 61133114 |
Jan 1984 |
JPX |
Non-Patent Literature Citations (3)
| Entry |
| Augnst et al.-International Journal of Pharmaceutics 33 (1986), 225-234. |
| Chemical Abstracts 88:55014e (Mayer et al.), 1978. |
| Nitto Electric Industrial Co., (1985) Chemical Abstracts 102 (18):354, Abstract No. 154817h. |
Continuation in Parts (3)
|
Number |
Date |
Country |
| Parent |
79801 |
Jul 1987 |
|
| Parent |
41793 |
Apr 1987 |
|
| Parent |
945356 |
Dec 1986 |
|
Patent Grant
4906463
